Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 43, 2013, Pages 17456-17461

  Donaldson, Joshua M ^a,b   Zer, Cindy ^a   Avery, Kendra N ^a   Bzymek, Krzysztof P ^a   Horne, David A ^a   Williams, John C ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cancer; Molecular recognition; Protein engineering

Indexed keywords

CETUXIMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PEPTIDE; RITUXIMAB; TRASTUZUMAB;

ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ARTICLE; BINDING SITE; BIOPHYSICS; CANCER CELL CULTURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ENGINEERING; SEQUENCE ANALYSIS; X RAY DIFFRACTION;

CANCER; MOLECULAR RECOGNITION; PROTEIN ENGINEERING;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING SITES; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICROSCOPY, FLUORESCENCE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDES; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SEQUENCE HOMOLOGY, AMINO ACID; SURFACE PLASMON RESONANCE;

EID: 84886410326     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1307309110     Document Type: Article

References (35)

1. Weiner LM, Murray JC, Shuptrine CW (2012) Antibody-based immunotherapy of cancer. Cell 148(6):1081-1084.
2. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12(4):278-287.
3. Desjarlais JR, Lazar GA (2011) Modulation of antibody effector function. Exp Cell Res 317(9):1278-1285.
4. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA (2005) BiTEs: Bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 10(18):1237-1244.
5. Goldenberg DM, et al. (2012) Pretargeted molecular imaging and radioimmunotherapy. Theranostics 2(5):523-540.
6. Pagel JM, et al. (2006) Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. Blood 108(1):328-336.
7. Yazaki PJ, et al. (2008) Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol 35(2):151-158.
8. Orcutt KD, et al. (2011) Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol 38(2):223-233.
9. Junutula JR, et al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26(8):925-932.
10. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9(10):767-774.
11. Wakankar AA, et al. (2010) Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: Changes due to modification and conjugation processes. Bioconjug Chem 21(9):1588-1595.
12. Sharkey RM, et al. (2005) Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 11(11):1250-1255.
13. Onda M, et al. (2011) Recombinant immunotoxin against B-cell malignancies with no immunogenicity inmiceby removal of B-cell epitopes.Proc Natl Acad Sci USA 108(14):5742-5747.
14. Cuesta AM, et al. (2012) Improved stability of multivalent antibodies containing the human collagen XV trimerization domain. MAbs 4(2):226-232.
15. Ducry L (2012) Challenges in the development and manufacturing of antibody-drug conjugates. Methods Mol Biol 899:489-497.
16. Ducry L, Stump B (2010) Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21(1):5-13.
17. Kamat V, et al. (2008) Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 7(5):726-733.
18. Riemer AB, et al. (2005) Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 97(22):1663-1670.
19. Li S, et al. (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7(4):301-311.
20. Graille M, et al. (2000) Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: Structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci USA 97(10):5399-5404.
21. Graille M, et al. (2001) Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the interaction modes of Fab binding proteins. Structure 9(8):679-687.
22. Derrick JP, Feavers I, Maiden MC (1999) Use of streptococcal protein G in obtaining crystals of an antibody Fab fragment in complex with a meningococcal antigen. Acta Crystallogr D Biol Crystallogr 55(Pt 1):314-316.
23. Graille M, et al. (2002) Evidence for plasticity and structural mimicry at the immunoglobulin light chain-protein L interface. J Biol Chem 277(49):47500-47506.
24. YoungWW, Jr., Tamura Y, Wolock DM, Fox JW (1984) Staphylococcal protein A binding to the Fab fragments of mouse monoclonal antibodies. J Immunol 133(6):3163-3166.
25. Torres M, Fernandez-Fuentes N, Fiser A, Casadevall A (2007) Exchanging murine and human immunoglobulin constant chains affects the kinetics and thermodynamics of antigen binding and chimeric antibody autoreactivity. PLoS ONE 2(12):e1310.
26. Rouhana J, et al. (2013) Kinetics of interaction between ADP-ribosylation factor-1 (Arf1) and the Sec7 domain of Arno guanine nucleotide exchange factor, modulation by allosteric factors, and the uncompetitive inhibitor brefeldin A. J Biol Chem288(7):4659-4672.
27. Cho HS, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421(6924):756-760.
28. Mammen M, Choi S, Whitesides G (1998) Polyvalent interactions in biological systems: Implications fordesignanduseofmultivalent ligandsandinhibitor.Angew Chem Int Ed 37:2755.
29. Rodeck U, et al. (1987) Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cell-independent effects. Cancer Res 47(14):3692-3696.
30. Nelson AL (2010) Antibody fragments: Hope and hype. MAbs 2(1):77-83.
31. Koefoed K, et al. (2011) Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 3(6):584-595.
32. Spangler JB, et al. (2010) Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci USA 107(30):13252-13257.
33. Baselga J, et al.; CLEOPATRA Study Group (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109-119.
34. Mossessova E, Lima CD (2000) Ulp1-SUMO crystal structure and genetic analysis reveal conserved interactions and a regulatory element essential for cell growth in yeast. Mol Cell 5(5):865-876.
35. Donaldson JM, Kari C, Fragoso RC, Rodeck U, Williams JC (2009) Design and development of masked therapeutic antibodies to limit off-target effects: Application to anti-EGFR antibodies. Cancer Biol Ther 8(22):2147-2152.